RxDoctor Payments Data

Ronald Dailey, MD

Internal Medicine · Brooklyn, NYNPI 1336252816

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 96 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$550
  • Johnson & Johnson$216
  • Merck$142
  • AstraZeneca$134
  • Gilead$129
  • AbbVie$115
  • plus $541 from 15 others

What the payments were for

  • Food & beverage$1,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,827 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,111
Medicare patients
138
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$179,460
TivicayDolutegravir Sodium62$147,689
DescovyEmtricitabine/Tenofov Alafenam61$142,117
TriumeqAbacavir/Dolutegravir/Lamivudi35$141,086
GenvoyaElviteg/Cob/Emtri/Tenof Alafen16$87,189
JulucaDolutegravir/Rilpivirine14$48,212
JardianceEmpagliflozin48$46,355
JanuviaSitagliptin Phosphate49$34,121
PrezcobixDarunavir/Cobicistat12$29,053
XareltoRivaroxaban23$25,345
OzempicSemaglutide18$25,031
EliquisApixaban19$23,268
FarxigaDapagliflozin Propanediol22$21,210
EdurantRilpivirine Hcl11$15,903
TradjentaLinagliptin19$14,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$129$408,766118 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca$550$336,987111 claims
Boehringer IngelheimJardiance, Tradjenta$74$61,18967 claims
Johnson & JohnsonPrezcobix, Xarelto$216$54,39835 claims
MerckJanuvia, Steglatro$142$37,74260 claims
Novo NordiskOzempic$105$25,03118 claims
PfizerEliquis$39$23,26819 claims
AstraZenecaFarxiga$134$21,21022 claims
AbbVieSynthroid$115$61712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →